The Correlation Between Leg Muscle Mass Index and Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus

References

• Chen XY, Cai CZ, Yu ML, et al. LB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway. World J Gastroenterol. 2019;25(45):6607–6618. doi:10.3748/wjg.v25.i45.6607
   PubMed Web of Science ®Google Scholar
• Ballestri S, Zona S, Targher G, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016;31(5):936–944. doi:10.1111/jgh.13264
   PubMed Web of Science ®Google Scholar
• Yang H, Suh DH, Kim DH, et al. Metabolomic and lipidomic analysis of the effect of pioglitazone on hepatic steatosis in a rat model of obese Type 2 diabetes. Br J Pharmacol. 2018;175(17):3610–3625. doi:10.1111/bph.14434
   PubMed Web of Science ®Google Scholar
• Li L, Huang Q, Yang L, et al. The association between Non-Alcoholic Fatty Liver Disease (NAFLD) and advanced fibrosis with serological vitamin B12 markers: results from the NHANES 1999–2004. Nutrients. 2022;14(6):1224.
   PubMed Web of Science ®Google Scholar
• American Diabetes A. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes-2021. Diabetes Care. 2021;44:S15–S33.
   PubMed Web of Science ®Google Scholar
• Abdelhameed RFA, Ibrahim AK, Elfaky MA, et al. Antioxidant and anti-inflammatory activity of cynanchum acutum L. Isolated flavonoids using experimentally induced type 2 diabetes mellitus: biological and in silico investigation for NF-kappaB Pathway/miR-146a expression modulation. Antioxidants. 2021;10(11):1713. doi:10.3390/antiox10111713
   Web of Science ®Google Scholar
• Bhanji RA, Narayanan P, Allen AM, Malhi H, Watt KD. Sarcopenia in hiding: the risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. Hepatology. 2017;66(6):2055–2065. doi:10.1002/hep.29420
   PubMed Web of Science ®Google Scholar
• Yang S, Yang G, Wu H, et al. MicroRNA-193b impairs muscle growth in mouse models of type 2 diabetes by targeting the PDK1/Akt signalling pathway. Diabetologia. 2022;65(3):563–581. doi:10.1007/s00125-021-05616-y
   PubMed Web of Science ®Google Scholar
• Pacifico L, Perla FM, Andreoli G, Grieco R, Pierimarchi P, Chiesa C. Nonalcoholic fatty liver disease is associated with low skeletal muscle mass in overweight/obese youths. Front Pediatr. 2020;8:158. doi:10.3389/fped.2020.00158
   PubMed Web of Science ®Google Scholar
• Araujo CG, de Souza ESCG, Laukkanen JA, et al. Successful 10-second one-legged stance performance predicts survival in middle-aged and older individuals. Br J Sports Med. 2022;56(17):975–980. doi:10.1136/bjsports-2021-105360
   PubMed Web of Science ®Google Scholar
• Seo JY, Cho EJ, Kim MJ, et al. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population. J Cachexia Sarcopenia Muscle. 2022;13(6):2953–2960. doi:10.1002/jcsm.13099
   PubMed Web of Science ®Google Scholar
• Charatcharoenwitthaya P, Karaketklang K, Aekplakorn W. Muscle strength, but not body mass index, is associated with mortality in patients with non-alcoholic fatty liver disease. J Cachexia Sarcopenia Muscle. 2022;13(5):2393–2404. doi:10.1002/jcsm.13001
   PubMed Web of Science ®Google Scholar
• Zhang W, Yang Z, Niu Y, et al. Association of calf circumference with insulin resistance and non-alcohol fatty liver disease: the REACTION study. BMC Endocr Disord. 2017;17(1):28. doi:10.1186/s12902-017-0176-4
   PubMedGoogle Scholar
• Murata Y, Kadoya Y, Yamada S, Sanke T. Sarcopenia in elderly patients with type 2 diabetes mellitus: prevalence and related clinical factors. Diabetol Int. 2018;9(2):136–142. doi:10.1007/s13340-017-0339-6
   PubMed Web of Science ®Google Scholar
• Wang X, Hu Z, Hu J, Du J, Mitch WE. Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling. Endocrinology. 2006;147(9):4160–4168. doi:10.1210/en.2006-0251
   PubMed Web of Science ®Google Scholar
• Aleman-Mateo H, Lopez Teros MT, Ramirez FA, Astiazaran-Garcia H. Association between insulin resistance and low relative appendicular skeletal muscle mass: evidence from a cohort study in community-dwelling older men and women participants. J Gerontol a Biol Sci Med Sci. 2014;69(7):871–877. doi:10.1093/gerona/glt193
   PubMed Web of Science ®Google Scholar
• Kim JA, Hwang SY, Chung HS, et al. Proportion and characteristics of the subjects with low muscle mass and abdominal obesity among the newly diagnosed and drug-naive type 2 diabetes mellitus patients. Diabetes Metab J. 2019;43(1):105–113. doi:10.4093/dmj.2018.0036
   PubMed Web of Science ®Google Scholar
• Bulur A, Sivritepe R. The association between non-alcoholic fatty liver disease and dynapenia in men diagnosed with type 2 diabetes mellitus. Healthcare. 2023;11(2):243. doi:10.3390/healthcare11020243
   Web of Science ®Google Scholar
• Jin R, Wang X, Li X, et al. Appendicular Skeletal Muscle Index and HbA1c evaluate liver steatosis in patients with metabolic associated fatty liver disease. Front Med. 2022;9:919502. doi:10.3389/fmed.2022.919502
   Web of Science ®Google Scholar
• Lee JH, Lee HS, Lee BK, Kwon YJ, Lee JW. Relationship between muscle mass and non-alcoholic fatty liver disease. Biology. 2021;10(2):122. doi:10.3390/biology10020122
   PubMedGoogle Scholar
• Van Dongen C, Paik JM, Harring M, et al. Sarcopenia, healthy living, and mortality in patients with chronic liver diseases. Hepatol Commun. 2022;6(11):3140–3153. doi:10.1002/hep4.2061
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. doi:10.1016/j.jhep.2019.06.021
   PubMed Web of Science ®Google Scholar
• Samuel VT, Shulman GI. Mechanisms for insulin resistance: common threads and missing links. Cell. 2012;148(5):852–871. doi:10.1016/j.cell.2012.02.017
   PubMed Web of Science ®Google Scholar
• Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol a Biol Sci Med Sci. 2014;69(5):547–558. doi:10.1093/gerona/glu010
   PubMed Web of Science ®Google Scholar